Top

Current Neurology and Neuroscience Reports

Published in:

01-09-2014 | Neuro-Oncology (LE Abrey, Section Editor)

Intracranial Cystic Lesions: A Review

Authors: Sophie Taillibert, Emilie Le Rhun, Marc C. Chamberlain

Published in: Current Neurology and Neuroscience Reports | Issue 9/2014

Abstract

Cysts and cystic-appearing intracranial lesions are common findings with routine cerebral imaging examination. These lesions often represent a challenge in diagnosis. Intracranial cystic lesions have wide pathologic and imaging spectra, of which some require an aggressive and tailored treatment, whereas many others remain asymptomatic and do not require follow-up or intervention. Intracranial cysts can be divided in non-neoplastic lesions that are often of developmental origin but comprise as well infectious cysts and neoplastic lesions that include benign cysts associated with low-grade tumors and cysts as a component of higher grade neoplasms. Reviewed are the pathology, origin, radiologic appearance, differential diagnosis, and therapeutic aspects of intracranial cystic lesions.

Osborn AG. Miscellaneous tumors, cysts, and metastases. In: Diagnostic neuroradiology. St Louis: Mosby; 1994. p. 631–49.

Katzman GL. Epidermoid cyst. In: Diagnostic imaging: brain. Salt Lake City, UT: Amirsys; 2004. p. I-7–16.

Kachhara R, Bhattacharya RN, Radhakrishnan VV. Epidermoid cyst involving the brain stem. Acta Neurochir (Wien). 2000;142:97.CrossRef

McLendon RE, Tien RD. Tumors and tumorlike lesions of maldevelopmental origin. In: Russell and Rubinstein’s pathology of tumors of the nervous system. 6th ed. New York: Oxford University Press; 1998. p. 327–52.

Dutt SN, Mirza S, Chavda SV, Irving RM. Radiologic differentiation of intracranial epidermoids from arachnoid cysts. Otol Neurotol. 2002;23:84–92.PubMedCrossRef

Osborn AG, Preece MT. Intracranial cysts: radiologic-pathologic correlation and imaging approach. Radiology. 2006;239:650–64.PubMedCrossRef

Schiff D, Hsu L, Wen PY. Uncommon brain tumors, skull base tumors, and intracranial cysts. In: Samuels MA, Feske S, editors. Office practice of neurology, 2nd edition. New York, NY: 2003. p. 1092.

Hamlat A, Hua ZF, Saikali S, et al. Malignant transformation of intra-cranial epithelial cysts: systematic article review. J Neurooncol. 2005;74:187.PubMedCrossRef

Katzman GL. Dermoid cyst. In: Diagnostic imaging: brain. Salt Lake City, UT: Amirsys; 2004b. p. I-7–12.

10.

Burger PC, Scheithauer BW, Vogel FS. Intracranial meninges. In: Surgical pathology of the brain and its coverings. 4th edition. Philadelphia, PA: Churchill Livingstone; 2002. p. 89–93.

11.

Stendel R, Pietilä TA, Lehmann K, et al. Ruptured intracranial dermoid cysts. Surg Neurol. 2002;57:391.PubMedCrossRef

12.

Canbaz B, Kemerdere R, Ocal E, Tanriverdi T. Intracranial dermoid cyst mimicking a giant thrombosed aneurysm. Neurol India. 2004;52:524.PubMed

13.

Macdonald RL. Colloid cysts in children. In: Berger MS, Prados MD, editors. Textbook of neuro-oncology. Philadelphia: Elsevier Saunders; 2005. p. 735.CrossRef

14.

Macdonald RL, Humphreys RP, Rutka JT, Kestle JR. Colloid cysts in children. Pediatr Neurosurg. 1994;20:169.PubMedCrossRef

15.

Spears RC. Colloid cyst headache. Curr Pain Headache Rep. 2004;8:297.PubMedCrossRef

16.

Osborn AG. Arachnoid cyst. In: Diagnostic imaging: brain. Salt Lake City, UT: Amirsys; 2004; p. I-7–4.

17.

Smith RA, Smith WA. Arachnoid cysts of the middle cranial fossa. Surg Neurol. 1976;5:246.PubMed

18.

Al-Holou WN, Terman S, Kilburg C, et al. Prevalence and natural history of arachnoid cysts in adults. J Neurosurg. 2013;118:222.PubMedCrossRef

19.

Rao G, Anderson R, Feldstein NA, Brockmeyer DL. Expansion of arachnoid cysts in children: report of two cases and review of the literature. J Neurosurg. 2005;102(3 Suppl):314.PubMed

20.

Osborn AG. Brain tumors and tumorlike masses: classification and differential diagnosis. In: Diagnostic neuroradiology. St Louis: Mosby; 1994. p. 408–30.

21.

Osborn AG. Choroid plexus cyst. In: Diagnostic imaging: brain. Salt Lake City, Utah: Amirsys; 2004. p. I-7–30.

22.

Osborn AG. Enlarged perivascular spaces. In: Diagnostic imaging: brain. Salt Lake City, UT: Amirsys; 2004. p. I-7–22.

23.

Osborn AG. Acquired metabolic, white matter, and degenerative diseases of the brain. In: Diagnostic neuroradiology. St Louis: Mosby; 1994. p. 751–2.

24.

Osborn AG. Neurenteric cyst. In: Diagnostic imaging: brain. Salt Lake City, UT: Amirsys; 2004. p. I-7–40.

25.

Harris CP, Dias MS, Brockmeyer DL, Townsend JJ, Willis BK, Apfelbaum RI. Neurenteric cysts of the posterior fossa: recognition management, and embryogenesis. Neurosurgery. 1991;29:893–7.PubMedCrossRef

26.

Osborn AG. Rathke cleft cyst. In: Diagnostic imaging: brain. Salt Lake City, UT: Amirsys; 2004f. p. II-2–16.

27.

Byun WM, Kim OL, Kim D. MR imaging findings of Rathke’s cleft cysts: significance of intracystic nodules. Am J Neuroradiol. 2000;21:485–8.PubMed

28.

Osborn AG. Porencephalic cyst. In: Diagnostic imaging: brain. Salt Lake City, UT: Amirsys; 2004g. p. I-7–36.

29.

Pawar SJ, Sharma RR, Mahapatra AK, Dev EJ. Giant ependymal cyst of the temporal horn: an unusual presentation—case report with review of the literature. Pediatr Neurosurg. 2001;34:306–10.PubMedCrossRef

30.

Osborn AG. Neuroglial cyst. In: Diagnostic imaging: brain. Salt Lake City, UT: Amirsys; 2004h. p. I-7–20.

31.

Osborn AG. Pineal cyst. In: Diagnostic imaging: brain. Salt Lake City, UT: Amirsys; 2004. p. I-7–26.

32.

Bruce JN, Stein BM. Pineal tumors. Neurosurg Clin N Am. 1990;1:123.PubMed

33.

Hellwig D, Bauer BL, List-Hellwig E. Stereotactic endoscopic interventions in cystic brain lesions. Acta Neurochir Suppl. 1995;64:59.PubMedCrossRef

34.

Koelsche C, Wöhrer A, Jeibmann A, et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol. 2013;125:891.PubMedCrossRef

35.•

Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397. Authors could discriminate different types of tumors according to their BRAF V600E status, thus, providing a new type of CNS tumor classification useful as a diagnostic tool and as a new lead in future clinical trials assessing targeted therapies in rare tumors sharing biomolecular patterns.PubMedCrossRef

36.

Horbinski C, Kofler J, Yeaney G, et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol. 2011;21:564.PubMedCentralPubMedCrossRef

37.•

Shih KC, Shastry M, Williams JT, et al. Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma. J Clin Oncol. 2014. This paper displays a clinical application of biomolecular researches recently conducted in the field of rare CNS tumors with the use of dabrafenib in a patient with a ganglioglioma.

38.•

Rush S, Foreman N, Liu A. Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol. 2013;31:e159. This paper displays a clinical application of biomolecular researches recently conducted in the field of rare CNS tumors with the use of vemurafenib in ganglioglioma.PubMedCrossRef

39.

Hassoun J, Söylemezoglu F, Gambarelli D, et al. Central neurocytoma: a synopsis of clinical and histologic features. Brain Pathol. 1993;3:297.PubMedCrossRef

40.

Kocaoglu M, Ors F, Bulakbasi N, et al. Central neurocytoma: proton MR spectroscopy and diffusion weighted MR imaging findings. Magn Reson Imaging. 2009;27:434.PubMedCrossRef

41.

Yang GF, Wu SY, Zhang LJ, et al. Imaging findings of extraventricular neurocytoma: report of 3 cases and review of the literature. Am J Neuroradiol. 2009;30:581.PubMedCrossRef

42.

Paek SH, Han JH, Kim JW, et al. Long-term outcome of conventional radiation therapy for central neurocytoma. J Neurooncol. 2008;90:25.PubMedCrossRef

43.

Kim CY, Paek SH, Jeong SS, et al. Gamma knife radiosurgery for central neurocytoma: primary and secondary treatment. Cancer. 2007;110:2276.PubMedCrossRef

44.

Bertalanffy A, Roessler K, Koperek O, et al. Recurrent central neurocytomas. Cancer. 2005;104:135.PubMedCrossRef

45.•

Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29:1408. The authors propose an integrative genomics approach to a cohort of 103 medulloblastomas patients to classify these tumors in 4 subgroups characterized by distinct demographics, clinical presentation, transcriptional profiles, genetic abnormalities, and clinical outcome. They showed that MB can be reliably assigned to subgroups through immunochemistry, thereby making MB subclassification widely available. These categories should be taken into account when designing a therapeutic trial in MB.PubMedCrossRef

46.

Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol. 2010;28:4961.PubMedCrossRef

47.•

Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol. 2011;29:1400. Since MB are heterogeneous and include relatively good-prognosis tumors, the authors underline the need to integrate in further clinical trial a practical stratification that permits accurate identification of risk and prognosis in order to be able to individualize adjuvant treatment and, thus, to minimize long-term adverse events in a subgroup of survivors. The authors could find 3 risk categories in childhood MB characterized by different molecular biomarker and clinical outcome.PubMedCentralPubMedCrossRef

48.

Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010;28:1345.PubMedCrossRef

49.•

Korshunov, A, Remke, M, Werft, W, et al. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol. 2010;28(18):3054–60. Since adult MB is distinct from pediatric MB in terms of genomic aberrations and their impact on clinical outcomes, it appears that adult MBs require age-specific risk stratification models. The authors propose a molecular staging system involving 3 distinct risk groups based on DNA copy number, status of 10q, and 17q in adult patients.

50.

Pfaff E, Remke M, Sturm D, et al. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol. 2010;28:5188.PubMedCrossRef

51.

Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29:1424.PubMedCentralPubMedCrossRef

52.

Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014;32:886.PubMedCrossRef

53.

Gimi B, Cederberg K, Derinkuyu B, et al. Utility of apparent diffusion coefficient ratios in distinguishing common pediatric cerebellar tumors. Acad Radiol. 2012;19:794.PubMedCrossRef

54.

Rumboldt Z, Camacho DL, Lake D, et al. Apparent diffusion coefficients for differentiation of cerebellar tumors in children. Am J Neuroradiol. 2006;27:1362.PubMed

55.•

Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173. The authors illustrate a clinical application of recent biomolecular findings in the fields of MB with the successful use of a hedgehog pathway inhibitor in 1 young adult patient.PubMedCrossRef

56.•

Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 2011;71:5057. The authors are addressing the issue of acquired resistance to hedgehog pathway inhibitors. Understanding these mechanisms is very important to overcome the current limitation of otherwise very promising agents.PubMedCrossRef

57.

Pérez-Martínez A, Lassaletta A, González-Vicent M, et al. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol. 2005;71:33.PubMedCrossRef

58.

Geyer JR, Sposto R, Jennings M, et al. Multi-agent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005;23:7621.PubMedCrossRef

59.

Timmermann B, Kortmann RD, Kühl J, et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol. 2006;24:1554.PubMedCrossRef

60.

Cohen BH, Zeltzer PM, Boyett JM, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Children’s Cancer Group randomized trial. J Clin Oncol. 1995;13:1687.PubMed

61.

Reddy AT, Janss AJ, Phillips PC, et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer. 2000;88:2189.PubMedCrossRef

62.

Ironside JW, Moss TH, Louis DN, et al. Vascular, Melanocytic and Soft Tissue Tumors. In: Diagnostic Pathology of Nervous System Tumors. New York: Churchill Livingstone; 2002. p. 189.

63.

Korshunov A, Sturm D, Ryzhova M, et al. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol. 2014;128(2):279–89.

64.

Depper MH, Hart BL. Pediatric Brain Tumors. In: Neuroimaging, Orrison WW, editor. Philadelphia, PA: WB Saunders; 2000. p. 1628.

65.

Gerber NU, von Hoff K, von Bueren AO, et al. Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006. J Neurooncol. 2011;102:459.PubMedCrossRef

66.

Woehrer A, Slavc I, Waldhoer T, et al. Incidence of atypical teratoid/rhabdoid tumors in children: a population-based study by the Austrian Brain Tumor Registry, 1996-2006. Cancer. 2010;116:5725.PubMedCrossRef

67.

Versteege I, Sévenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203.PubMedCrossRef

68.

Bruggers CS, Bleyl SB, Pysher T, et al. Clinicopathologic comparison of familial vs sporadic atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system. Pediatr Blood Cancer. 2011;56:1026.PubMedCentralPubMedCrossRef

69.

Eaton KW, Tooke LS, Wainwright LM, et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer. 2011;56:7.PubMedCentralPubMedCrossRef

70.

Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg. 1996;85:56.PubMedCrossRef

71.

Buscariollo DL, Park HS, Roberts KB, Yu JB. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a surveillance, epidemiology, and end results analysis. Cancer. 2012;118:4212.PubMedCrossRef

72.

Athale UH, Duckworth J, Odame I, Barr R. Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol. 2009;31:651.PubMedCrossRef

73.

Tekautz TM, Fuller CE, Blaney S, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005;23:1491.PubMedCrossRef

74.

Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009;27:385.PubMedCentralPubMedCrossRef

75.

De Amorim Bernstein K, Sethi R, Trofimov A, et al. Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors. Int J Radiat Oncol Biol Phys. 2013;86:114.PubMedCrossRef

76.

Pimentel J, Fernandes A, Távora L, et al. Benign isolated fibrohistiocytic tumor arising from the central nervous system. Considerations about two cases. Clin Neuropathol. 2002;21:93.PubMed

77.

Doppenberg EMR, Zacko JC, Chen MY, Broaddus WC. Fibrous tumors. In: Berger MS, Prados MD, editors. Textbook of Neuro-oncology. Philadelphia: Elsevier Saunders; 2005. p. 282.CrossRef

78.

Akimoto J, Takeda Y, Hasue M, et al. Primary meningeal malignant fibrous histiocytoma with cerebrospinal dissemination and pulmonary metastasis. Acta Neurochir (Wien). 1998;140:1191.CrossRef

79.

Neumann HP, Eggert HR, Weigel K, et al. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg. 1989;70:24.PubMedCrossRef

80.

Aldape KD, Plate KH. Vortmeyer AO, et al Haemangioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the nervous system. Lyon: IARC Press; 2007.

81.

Waldmann TA, Levin EH, Baldwin M. The association of polycythemia with a cerebellar hemangioblastoma. The production of an erythropoiesis stimulating factor by the tumor. Am J Med. 1961;31:318.PubMedCrossRef

82.

Kühne M, Sidler D, Hofer S, et al. Challenging manifestations of malignancies. Case 1. Polycythemia and high serum erythropoietin level as a result of hemangioblastoma. J Clin Oncol. 2004;22:3639.PubMedCrossRef

83.

Bohling T, Hatva E, Plate KH, et al. Von Hippel-Lindau disease and capillary haemangioblastoma. In: Kleihues P, Cavenee WK, editors. Tumor of the nervous system pathology and genetics. Lyon: IARC Press; 1997. p. 179.

84.

Burger PC, Scheithauer BW. Tumors of the central nervous system. Washington: Armed Forces Institute of Pathology; 1994. p. 239.

85.

Omulecka A, Lach B, Alwasiak J, Gregor A. Immunohistochemical and ultrastructural studies of stromal cells in hemangioblastoma. Folia Neuropathol. 1995;33:41.PubMed

86.

Gläsker S, Bender BU, Apel TW, et al. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry. 2001;70:644.PubMedCentralPubMedCrossRef

87.

Gijtenbeek JM, Jacobs B, Sprenger SH, et al. Analysis of von Hippel-Lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity. J Neurosurg. 2002;97:977.PubMedCrossRef

88.

Krieg M, Marti HH, Plate KH. Co-expression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood. 1998;92:3388.PubMed

89.

Frantzen C, Kruizinga RC, van Asselt SJ, et al. Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease. Neurology. 2012;79:793.PubMedCrossRef

90.

Weil RJ, Lonser RR, DeVroom HL, et al. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98:95.PubMedCrossRef

91.

Eskridge JM, McAuliffe W, Harris B, et al. Preoperative endovascular embolization of craniospinal hemangioblastomas. Am J Neuroradiol. 1996;17:525.PubMed

92.

Moss JM, Choi CY, Adler Jr JR, et al. Stereotactic radiosurgical treatment of cranial and spinal hemangioblastomas. Neurosurgery. 2009;65:79.PubMedCrossRef

93.

Koh ES, Nichol A, Millar BA, et al. Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system. Int J Radiat Oncol Biol Phys. 2007;69:1521.PubMedCrossRef

94.

Forsyth PA, Shaw EG, Scheithauer BW, et al. Supratentorial pilocytic astrocytomas. A clinicopathologic, prognostic, and flow cytometric study of 51 patients. Cancer. 1993;72:1335.PubMedCrossRef

95.

Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68:8673.PubMedCentralPubMedCrossRef

96.

Armstrong GT, Conklin HM, Huang S, et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol. 2011;13:223.PubMedCentralPubMedCrossRef

97.

Ellis JA, Waziri A, Balmaceda C, et al. Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol. 2009;95:377.PubMedCrossRef

98.

Fangusaro J, Gururangan S, Poussaint TY, et al. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 2013;119:4180.PubMedCrossRef

99.

Maldaun MV, Suki D, Lang FF, Prabhu S, Shi W, Fuller GN, et al. Cystic glioblastoma multi-form: survival outcomes in 22 cases. J Neurosurg. 2004;100(1):61–7.PubMedCrossRef

100.

Kaur G, Bloch O, Jian BJ, Kaur R, Sughrue ME, Aghi MK, et al. A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. J Neurosurg. 2011;115(4):754–9.PubMedCrossRef

101.

Utsuki S, Oka H, Suzuki S, Shimizu S, Tanizaki Y, Kondo K, et al. Pathological and clinical features of cystic and noncystic glioblastomas. Brain Tumor Pathol. 2006;23(1):29–34.PubMedCrossRef

102.

Adn M, Saikali S, Guegan Y, Hamlat A. Pathophysiology of glioma cyst formation. Med Hypotheses. 2006;66(4):801–4.PubMedCrossRef

103.

Reddy JS, Mishra AM, Behari S, et al. The role of diffusion-weighted imaging in the differential diagnosis of intracranial cystic mass lesions: a report of 147 lesions. Surg Neurol. 2006;66(3):246–50.PubMedCrossRef

104.

Mishra AM, Gupta RK, Jaggi RS, et al. Role of diffusion-weighted imaging and in vivo proton magnetic resonance spectroscopy in the differential diagnosis of ring-enhancing intracranial cystic mass lesions. J Comp Assist Tomogr. 2004;28:540–7.CrossRef

105.

Ebinu JO, Lwu S, Monsalves E, Arayee M, Chung C, Laperriere NJ, et al. Gamma knife radiosurgery for the treatment of cystic cerebral metastases. Int J Radiat Oncol Biol Phys. 2013;85(3):667–71.PubMedCrossRef

106.

Higuchi F, Kawamoto S, Abe Y, Kim P, Ueki K. Effectiveness of a 1-day aspiration plus Gamma Knife surgery procedure for metastatic brain tumor with a cystic component. J Neurosurg. 2012;117(Suppl):17–22.PubMed

107.

Liu X, Yu Q, Zhang Z, Zhang Y, Li Y, Liu D, et al. Same-day stereotactic aspiration and Gamma Knife surgery for cystic intracranial tumors. J Neurosurg. 2012;117(Suppl):45–8.PubMed

108.

Yamanaka Y, Shuto T, Kato Y, Okada T, Inomori S, Fujino H, et al. Ommaya reservoir placement followed by Gamma Knife surgery for large cystic metastatic brain tumors. J Neurosurg. 2006;105(Suppl):79–81.PubMed

109.

Salzman KL. Parasites, miscellaneous. In: Diagnostic imaging: brain. Salt Lake City, Utah: Amirsys; 2004; I-8–53.

110.

Osborn AG. Infections of the brain and its linings. In: Diagnostic neuroradiology. St Louis, MO: Mosby; 1994inf. p. 709–13.

111.

Garcia HH, Gonzalez AE, Evans CA, Gilman RH. Taenia solium cysticercosis. Lancet. 2003;362(9383):547–54.PubMedCentralPubMedCrossRef

112.

Nash TE, Pretell EJ, Lescano AG, et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol. 2008;7:1099.PubMedCentralPubMedCrossRef

113.•

Baird RA, Wiebe S, Zunt JR, et al. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;80:1424. This is a report of the Guideline Development Subcommittee of the American Academy of Neurology proposing evidence-based guideline for the medical treatment of neurocysticercosis. Respective roles of cysticidal drugs and steroids are detailed based on the data of the literature.PubMedCentralPubMedCrossRef

114.

Rangel-Castilla L, Serpa JA, Gopinath SP, et al. Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg. 2009;80:373.PubMed

115.

Ellison D, Love S, Chimelli L, Harding BN, Lowe J, Vinters H. Parasitic infections. In: Neuropathology: a reference text of CNS pathology. 2nd ed. Philadelphia: Mosby; 2004. p. 379–81.

Title: Intracranial Cystic Lesions: A Review
Authors: Sophie Taillibert
Emilie Le Rhun
Marc C. Chamberlain
Publication date: 01-09-2014
Publisher: Springer US
Published in: Current Neurology and Neuroscience Reports / Issue 9/2014
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-014-0481-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intracranial Cystic Lesions: A Review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2014

Hypertonic Saline for the Treatment of Intracranial Hypertension

Neuromyelitis Optica Spectrum Disorders

The Molecular Landscape of Pediatric Brain Tumors in the Next-Generation Sequencing Era

Using Structural and Diffusion Magnetic Resonance Imaging To Differentiate the Dementias

The Role of Olfactory Challenge Tests in Incipient Dementia and Clinical Trial Design

Hashimoto’s Encephalopathy: A Brief Review